Most patients with psoriatic arthritis (PsA) failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated.

Moreover, patients became increasingly less likely to see substantial symptom improvement as they moved on to third-, fourth, and later-line treatments, reported Bente Glintborg, MD, PhD, of University Hospital of Copenhagen, and colleagues in the Annals of the Rheumatic Diseases.